INmune Bio Updates Shareholders on Clinical Progress for CORDStrom™ and XPro™, Extends Cash Runway

summarizeSummary

Inmune Bio issued a shareholder letter detailing significant clinical progress for its CORDStrom™ and XPro™ programs, including upcoming regulatory submissions and refined trial strategies, alongside an extended cash runway through 2026.

check_boxKey Events

• CORDStrom™ Program Advances Towards Regulatory Filings

  The company is preparing a Marketing Authorization Application (MAA) for CORDStrom™ in the UK by mid-2026, followed by a Biologics License Application (BLA) in the U.S. by late 2026 for Recessive Dystrophic Epidermolysis Bullosa (RDEB).

• XPro™ Alzheimer's Trial Shows Promise in Subpopulation

  Despite the broader Phase 2 MINDFuL trial not meeting its primary endpoint, XPro™ demonstrated meaningful cognitive and biomarker signals in a predefined subpopulation of early Alzheimer's patients with neuroinflammation, informing future development.

• Extended Financial Runway

  Inmune Bio reported $27.7 million in cash and cash equivalents as of September 30, 2025, providing sufficient funds to support operations through year-end 2026.

auto_awesomeAnalysis

Inmune Bio provided a comprehensive shareholder update detailing significant progress across its key clinical programs and financial position. The CORDStrom™ program for RDEB is advancing towards Marketing Authorization Application (MAA) in the UK by mid-2026 and a Biologics License Application (BLA) in the U.S. by late 2026, marking critical regulatory milestones. For the XPro™ Alzheimer's disease trial, while the broader Phase 2 MINDFuL study did not meet its primary endpoint, the company identified meaningful signals in a predefined subpopulation of early AD patients with neuroinflammation, providing a refined path forward for registrational trials. The company also reported a strong cash position of $27.7 million as of September 30, 2025, which is expected to fund operations through year-end 2026, providing crucial financial stability for a clinical-stage biotech.